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ABSTRACT 
Background. The Cancer Drugs Fund (CDF) was introduced to provide cancer patients in England 
with access to drugs not appraised or approved by the National Institute for health and Care 
Excellence (NICE).  We studied press coverage of the CDF in UK newspapers in 2010-15. 
Methods.  Newspaper stories in the Factiva database were sought, and details copied to a spreadsheet.  
They were categorised by whether they were supportive or critical of the CDF, which drugs they 
mentioned and for which cancers. 
Results.  Press coverage was mainly very positive, arguing for the CDF’s extension to Scotland and 
Wales, and a bigger budget, but neglecting the lack of patient benefit and the severe side effects that 
sometimes occurred.  Leading this support was the Daily Mail, whose influence (measured by the 
product of number of stories and the paper’s circulation) was almost greater than that of the other 
newspapers combined. 
Conclusions.  Although there was some  critical analysis of the CDF, ,our analysis shows that most 
press coverage was largely positive, and unrepresentative in comparison with the lack of overall 
benefits to patients and society.  It is likely that it contributed to the CDF’s continuation despite 
mounting evidence of its ineffectiveness. 
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KEY MESSAGES:  
 
• The Daily Mail, the Daily Telegraph and The Times published the greatest volume of 
news stories regarding the CDF 
 
• The Daily Mail had the greatest “influence” of the newspapers, based on the product 
of number of stories and circulation 
 
• The majority of news stories regarding the CDF were positive calling for an increase 
in coverage to the devolved UK territories and for greater funding. 
 
• Of the news stories mentioning specific drugs, abiraterone, bevacizumab and 
trastuzumab were the most frequently cited.  
 
• CDF stories related to particular tumour types were not in keeping with their relative 
burden as measured by DALYs, with breast cancer over-represented in news articles 
compared to lung cancer which was under-represented. 
 
BACKGROUND 
The Cancer Drugs Fund was established by the UK coalition government in 2010 to provide 
access to drugs not available through the English NHS. Some of the drugs available through 
the fund awaited formal assessment by NICE (National Institute for Health and Care 
Excellence), whilst others had been previously appraised but not recommended for routine 
funding by the NHS. In 2011, the Cancer Drugs Fund had an annual budget of £200m. The 
lifespan of the fund was extended over time, along with its budget (increasing to £340 million 
in 2015-16). However, even though two re-prioritisation exercises were undertaken, the final 
outturn position for 2015/16 was £466m - an overspend of £126m (37%).Close to £1.4 billion 
in total has been spent on cancer drugs through this fund.1 2 The CDF has subsequently been 
reconfigured and is now under the control of NICE.2 
An analysis of the CDF between 2010 and 2015 has shown that it delivered poor value for tax 
payers and for patients, with only 38% of approved drugs achieving a statistically significant 
improvement in overall survival and only 18% meeting thresholds for a clinically meaningful 
benefit according to value scales developed by professional bodies.3 Put simply, many of 
these drugs did not offer any benefit with respect to prolongation of life or improvement in 
quality of life, and access was achieved at considerable financial and opportunity cost with 
little evidence that patients on the fund benefited.   
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The CDF was created following intense public and political pressure to provide access no 
matter what the cost or the evidence for their benefit.  This was a debate played out in the 
media, which resulted in a changing role for NICE and the creation of the CDF.4 In this 
analysis, we have sought to investigate the volume and representativeness of media reporting 
about the CDF between 2010-2015, specifically highlighting key differences between media 
outlets in their support for, or opposition to, the fund, and the likely impact on public and 
political perception given the “impact” or “influence” of particular newspapers. We also 
assessed the drugs most frequently cited in newspaper reports to see whether any 
concordance existed with actual prescribing patterns.  
METHODS 
Inclusion criteria 
The full-text database Factiva © Dow Jones was searched between 1 January 2010 and 31 
December 2015 for stories in the nine national newspapers that have a circulation across the 
UK (see Table 1) that contained the phrase "cancer drugs fund". The stories were retained for 
analysis (by PR and GL) only if the CDF was the main focus of the story.   
The full text of each story meeting the inclusion criteria was analysed thematically and the 
following information collected: the story's date, the newspaper, the headline and the 
synopsis, as well as the word count.  Details of the journalist’s name and position (if given), 
the names of the drugs and the cancer site for which they were intended to be used, were also 
recorded. Higher thematic codes were derived as either positive (supporting the CDF), 
neutral, or negative (critical of it). In conjunction with the higher “sentiment” themes,  
subject area themes were also coded. The codes were modified iteratively7during the analysis 
of the stories.  The codings were developed by PR and RS, and if there was disagreement, 
there was discussion with AA and GL to resolve the issue.  For example, positive newspaper 
stories were identified that advocated a widening of the geographical coverage of the CDF 
beyond England to the other devolved territories (e.g. Wales).  Similarly, negative stories 
about the CDF were identified that focused on the effect that the CDF had in re-directing 
money away from other areas of the NHS.  Further analyses sought to measure the 
comparative “influence” of each newspaper’s reporting of the CDF with a  metric specifically 
developed for this evaluation.  This was determined for each of the nine newspapers as the 
product of its circulation (obtained from the Audit Bureau of Circulation, 
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https://www.abc.org.uk/) and the number of stories. Influence was calculated with and 
without the inclusion of the length of the article (word count). 
In addition, we analysed whether there was any concordance between the types of cancer 
mentioned in the newspaper reports and the burden of disease from each tumour type in the 
UK in 2010 measured in Disability Adjusted Life Years (DALYs).5  This indicator sums the 
reduction in life expectancy (e.g. premature mortality compared with Japan, with the highest 
life expectancy) and the number of years spent living at less than full health (disability).  The 
DALY gives a better measure of disease burden from different cancers by including 
morbidity and mortality.  .  The analysis is designed to assess whether newspaper coverage of 
particular tumour types correlates with their health burden on the population. 
RESULTS 
Outputs of stories in the different newspapers 
Out of a total of 1692 stories that mentioned the Cancer Drugs Fund, we excluded 1310 that 
were about other topics and only mentioned the CDF peripherally.  In the 382 media stories 
retained for analysis that discussed the CDF in some detail, 44 different cancer drugs were 
identified, 16 different cancer sites were mentioned and 142 different journalists were named 
as authors.  Following the launch of the CDF in 2010, coverage (the number of published 
stories) was fairly steady from 2010 to 2012 and thenincreased from 2012 to 2015 (Figure 1).  
The Daily Mail had the greatest calculated influence (based on frequency of stories and 
newspapers circulation (Table 1).  Including article length, which quantified whether an 
article was a minor item or feature story, made no difference to the rank of CDF reported 
‘influence’, therefore the simpler, frequency of story x circulation calculation is used.  The 
table makes clear that the Daily Mail had almost as much influence as the other eight daily 
papers together, and that this was more than three times the influence of any other paper 
according to our metric.  
The tone of the stories and the weight of opinion 
Eleven broad themes were identified.   The codes and their relative frequency are listed in 
Table 2.  Seven of the codes related to positive reporting of the cancer drugs fund (in green), 
three related to negative reporting (in red) and one was neutral (black). 
Figure 2 demonstrates the editorial balance of stories about the CDF (positive, neutral and 
negative) for each individual newspaper. For four newspapers the majority of their stories 
were consistently positive regarding the CDF (Daily Mail, The Sun, Daily Express and Daily 
 5 
Mirror), one was more negative (Financial Times) and the four remaining newspapers 
showed a mixed picture of positive, negative and neutral tones in their stories. The 
combination of this chart, Table 2 and the influence scores shown in Table 1, illustrates the 
significant positive reportage of the CDF overall, particularly in the Daily Mail.   
The dominant narrative was one of praise for the CDF in providing access to drugs that were 
needed by cancer patients, but had previously been denied.  Where the narrative was not 
wholly supportive thefollowing trade-offs were described: (1) There was a view that the CDF 
was great, but since it only applied to England, and not Wales or Scotland, it was unfair.  (2) 
Although the CDF benefited some patients, it also distorted NHS spending and was limited to 
helping only a small group of patients.  Possible side effects from the new drugs were only 
mentioned in one story in the Financial Times and one in The Guardian.  
The cancer drugs and cancer types most often mentioned 
The cancer drugs that featured in the newspaper stories were sometimes referred to by their 
brand names, and sometimes by their "scientific" names.  Although there were 216 CDF 
stories that mentioned specific drugs, the stories were dominated by three systemic therapies, 
namely bevacizumab (34 mentions, 15% of all drugs cited), trastuzumab emtasine (33 
mentions, 15%) and abiraterone (19 mentions, 9%), see Table 3.  The national audit office 
found in its review of CDF-related prescribing that both bevacizumab and abiraterone were 
the most commonly prescribed drugs in the CDF in 2013/2014 and 2014/2015 accounting for 
19% and 11% of all prescriptions respectively.8  
A particular concern relates to the prescribing of bevacizumab.  It was approved for up to 
nine indications in the CDF for a variety of tumour types including colorectal, breast, 
ovarian, and cervical cancers. A recent analysis found that none of these indications would 
have met European Society for Medical Oncology (ESMO) clinical thresholds for meaningful 
benefit, and only one indication would meet American Society of Clinical Oncology (ASCO) 
criteria.3   
In addition, coverage of affected cancer sites did not reflect the most commonly occurring 
cancers (incidence) nor those causing the greatest burden, measured in DALYs5.  Figure 3 
compares the numbers of mentions of individual cancer sites with the burden of disease in the 
UK in 2010 relative to all cancers.  Breast, prostate and colorectal cancer received 
significantly greater media coverage than other cancer sites, and in particular, lung cancer.  
This is in keeping with breast cancer's greater proportional coverage among all cancer stories: 
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it has the most research stories on the BBC and in European newspapers.9,10  Lung cancer, by 
contrast, is the leading cause of cancer mortality and disease burden5, but was only mentioned 
four times.  
DISCUSSION 
Our analysis has shown that there was substantial newspaper media support for the CDF, 
with our "influence" measure, based on the product of number of articles published and 
newspaper circulation, showing three times as much in favour as against.  There is a potential 
concern therefore about the influence of media reporting on both demand for, and subsequent 
access to the drug through the CDF, although a causal link cannot be proved.   
In light of the return of the CDF to the NICE cost-effectiveness umbrella from July 2016, it is 
important to reflect on the potential influence of reporting on the execution of the public 
policy that led to the CDF.  Media reports did not scrutinise the discrepancy between those 
drugs available on the CDF and those diseases with the greatest health burden, the toxicities 
of the medicines, nor the opportunity cost of the CDF for other cancer treatments.  Reportage 
in some of the most influential newspapers also failed to appraise why some cancer 
medicines were funded and others were not in the context of a publicly-funded health system 
and public preferences for care in incurable disease.  Access at any cost was a clear totem 
around which the pro-CDF media based its coverage.  The views of experts who pointed out 
the intrinsic unfairness of the CDF or the lack of efficacy of, and unpleasant side effects 
from, many of the drugs seem to have counted for little against the human interest stories of 
individual patients.  This is in keeping with evidence from an analysis of American media 
coverage of cancer which found that adverse events from cancer treatment were rarely 
discussed.8 
In many respects the extensive coverage of the CDF closely mirrors a major media 
preoccupation with cancer.  Although cancer is responsible for only 21% of DALYs in the 
UK, there are many more newspaper stories about research on cancer than about the other 
main causes of the UK disease burden, cardiovascular disease (including stroke) and mental 
disorders.5 11  Furthermore, the focus on cancer medicines is also notable.  The preponderance 
of stories on chemotherapy9, compared with surgery and radiotherapy, has probably 
contributed to a strong public perception that the best way to help cancer patients and 
improve outcomes is to allow them access to new (and expensive) medicines, whose 
performance is often hyped and gives rise to unreasonable expectations.112-151-14  The reason 
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for the pre-eminence of chemotherapy in cancer journalism is not clear but is likely to be 
related to the volume of press releases by both public and private sectors on the outputs of the 
global cancer research endeavour, which is disproportionally focused on fundamental cancer 
biology, new medicines and biomarkers.16,17 
In an era of ‘alternative facts’ it is imperative that health journalists maintain their credibility 
by being critical of the "next big thing" or “game changer” and that the research funders and 
institutions assist them in their work.  In the face of the escalating costs of the CDF and its 
failure to demonstrate measurable improvements in life expectancy or quality of life for the 
patients who were treated, it is important to consider whether unrepresentative media 
coverage contributed to the longevity of the CDF and the policy mis-direction that occurred.  
In addition to highlighting editorial policies in the print media, this study also draws attention 
to the failure of many public organisations, including charitable research funders in the UK, 
to publicise the shortcomings of the CDF.  This also must be considered in the context that 
there is no evidence that ring-fencing drug-only spending for cancer will improve outcomes 
for cancer patients over and above greater investment in the whole cancer management 
pathway (screening, diagnostics, radiotherapy, surgery and palliative care). 
Our study was limited to the reportage in nine national newspapers, and did not cover other 
sources of public information such as broadcasts and social media. The exclusion of 
newspapers from the other UK territories was justifiable because the CDF operated only in 
England.  It is also important to stress that we are not able to prove causality between media 
reporting and the longevity of the CDF.  In future, it would be desirable to complement this 
study with a qualitative analysis of how the media affected the policy-makers and physicians 
who were principally involved.  It would also be worthwhile to interview some of the leading 
journalists in order to discover the frames and drivers that they experienced for their 
reportage. 
In summary, our analysis demonstrates that the media coverage around the NHS Cancer 
Drugs Fund, was largely positive, and unrepresentative in comparison with the lack of overall 
benefits to patients and society of the Cancer Drugs Fund, which has since undergone a 
substantial overhaul.  In addition, many of the articles espoused the virtues of particular drugs 
such as bevacizumab, which failed to deliver improvement in survival or quality of life for 
several tumour types according to the original trial evidence.  It is possible that the skewed 
media coverage influenced demand and subsequent access for particular drugs through the 
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fund, and therefore brings into question the fairness from a public policy perspective of the 
NHS Cancer Drugs Fund.  However, it is important to point out that a number of senior 
correspondents, commentators and media outlets (e.g. The Guardian) did attempt to redress 
the balance.  But compared with the positive reporting and wide distribution of the other UK 
national newspapers, they were lone voices in the wilderness.  
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Tables 
Table 1.  Amount of influence of individual newspapers in their stories about the Cancer 
Drugs Fund, based on product of circulation in 2014, number of stories and mean length in 
words. DML = Daily Mail; SUN = The Sun; TEL = Daily Telegraph; MIR = Daily Mirror; 
DEX = Daily Express; TIM = The Times; IND = The Independent (and i); GDN = The 
Guardian; FIT = Financial Times 
 Stories Mean words Total words Circulation, k Influence Percent 
DML 82 596 48887 1780 145960 46.3 
SUN 29 379 10989 2210 41990 13.3 
TEL 57 476 27106 550 31350 9.9 
MIR 49 526 25766 990 28710 9.1 
DEX 56 422 23637 500 24500 7.8 
TIM 19 465 8831 380 21280 6.7 
IND 29 619 17939 370 10730 3.4 
GDN 28 798 22343 210 5880 1.9 
FIT 22 638 14026 230 5060 1.6 
Total 371   199523 7220 315460 100.0 
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Table 2.  Qualitative codes for CDF stories 
Code Significance of the newspaper story Number of stories 
GEO the CDF should have a wider geographical coverage (Wales, 
Scotland) 
88 
MON the CDF is good, but would benefit from more money 60 
GOO the CDF is good generally 29 
PEO the CDF is good and is helping people, including named 
individuals 
23 
DRU the CDF is good, but should cover more drugs 10 
AVA the CDF is good generally but in a context of attacking the NHS: 
e.g  this drug should be available generally, not just via the 
special fund 
9 
OTH the CDF is good, but should also cover other cancer treatments 2 
NEU does not say CDF is good or bad (balanced/neutral) 84 
NHS the CDF is bad because it takes money from the rest of the NHS 59 
NIC the CDF is bad because it undercuts the evidence-based NICE 
recommendations 
9 
LOB the CDF is bad because it is the result of lobbying by drug 
companies and/or patient groups 
8 
SID the CDF is bad because the drugs are ineffective and have nasty 
side-effects 
2 
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Table 3.  Individual cancer drugs mentioned in the newspaper stories, with numbers of 
mentions. 
 
Trade name Scientific name N   Trade name Scientific name N 
Avastin bevacizumab 34   Jevtana cabazitaxel 2 
Kadcyla trastuzumab emtansine 33   Soliris eculizumab 2 
Zytiga abiraterone 19   Sprycel dasatinib 2 
Xtandi enzalutamide 11   Tarceva erlotinib 2 
Erbitux cetuximab 10   Xalkori crizotinib 2 
Yervoy ipilimumab 9   Alimta pemetrexed 1 
Zelboraf vemurafenib 8   Arzerra ofatumumab 1 
Halaven eribulin 7   Campath alemtuzumab 1 
Perjeta pertuzumab 7   Gleevec imatinib 1 
Tyverb lapatinib 7   Glucophage metformin 1 
Lynparza olaparib 6   Ibrance palbociclib 1 
Nexavar sorafenib 6   Imnovid pomalidomide 1 
Sutent sunitinib malate 6   Keytruda pembrolizumab 1 
Abraxane protein-bound paclitaxel 4   Mabthera rituximab 1 
Opdivo nivolumab 4   Sertex serratiopeptidase 1 
Vedotin brentuximab 4   Sovaldi sofosbuvir 1 
Gleevec imatinib 3   Stivarga regorafenib 1 
Revlimid lenalidomide 3   Synribo omacetaxine 1 
Afinitor everolimus 2   Tasigna nilotinib 1 
Bosulif bosutinib 2   Taxol paclitaxel 1 
Herceptin trastuzumab 2   Taxotere docetaxel 1 
Inlyta axitinib 2   Vectibix panitumumab 1 
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Figure legends 
Figure 1.  Numbers of stories about the Cancer Drugs Fund in nine national UK newspapers, 
2010-15.  For codes, see Table 1. (Sunday Times stories excluded as it is not a daily 
newspaper). 
Figure 2.  The tone of the cancer drugs fund stories in the 10 newspapers, 2010-15.  For 
newspaper codes see Table 1 and for story character codes see Table 2. Green solid/shaded: 
positive reporting of CDF; White: neutral or balanced; Red-Pink solid/shaded: negative 
reporting of CDF. 
Figure 3.  Comparison of numbers of mentions of cancer sites in CDF stories, 2010-15, with 
relative disease burden in the UK from cancers at these sites, 2010.  
 
